Introduction
Direct spinal application of opiates produces a significant reduction in the response to high intensity, potentially tissue-damaging stimuli. 1 Intrathecal opioids are also very effective for the treatment of neuropathic rats. 2 This spinal antinociceptive effect is believed to be mediated through opioid binding that takes place in the spinal dorsal horn, at sites pre-and postsynaptic to the primary afferent terminal. [3] [4] [5] At these sites, the opioid agonists act to block afferent excitatory-transmitter release, [6] [7] [8] and depress the excitability of second-order neurons. 9, 10 It has proved to be a relatively safe method because, despite the presence of significant numbers of opioid-binding and enkephalin-containing terminals in the intermediolateral (IML) cell column and the dorsal horn of the spinal cord, 10 intrathecal administration of mu and delta agonists has little effect on resting heart rate and blood pressure. These data indicate that intrathecal opioid administration provides a potential solution for chronic pain syndromes, especially the endogenous opioid, because of reduced tolerance and dependence during pain management. 11 It seems reasonable to suggest that the provision of long-term pain control by modulation of pain through in vivo gene transfer may also prove efficacious. Gene trans- fer using viral vectors (retroviral and adenoviral) is achieved through the infectivity of the viral particles. Although mammalian virus-based vectors have gained wide acceptance for this transfer, their use has been associated with several problems. Retroviral vectors require replicating cells for integration and expression, and carry only relatively small segments of deoxyribonucleic acid (DNA). 12, 13 Furthermore, adenoviral vectors necessitate repeat administration due to their transient expression, with strong associated antigenicity. By contrast, nonviral gene-transfer systems, which use naked plasmid DNA, are considered reliable and simple. 14, 15 Unlike viral vectors, the introduction of the plasmid DNA into target cells is facilitated by chemical or physical methods. [16] [17] [18] [19] Electroporation is a physical method of introducing macromolecules into cells in vitro by applying a brief electrical pulse that causes transient membrane transit of molecules, providing higher transfer efficiency compared with other nonviral transformation methods. 19, 20 For the present study, a novel method was developed for spinal cord-confined gene transfer in vivo. The optimal conditions of intrathecal electroporation for the expression of pro-opiomelanocortin (POMC) gene were determined initially by Western blot. Then, it was demonstrated that POMC gene therapy can alleviate neuropathic pain caused by chronic constrictive injury (CCI) of the sciatic nerve in a rat model.
Results

Optimal conditions for POMC electroporation in vivo
The optimal voltage level for the pulses was determined, with the pulse number (n = 5) and duration (50 ms) fixed, with mean beta-endorphin immunoactivity increasing up to 200 V (Figure 1a) .
Optimal pulse duration was determined with the pulse number (n = 5) and voltage (200 V) fixed (Figure 1b) , with the mean beta-endorphin immunoactivity increasing up to 75 ms.
The optimal number of shocks was determined with 23% of the maximal value at 21 days after electroporation. Similar findings were noted in the study of RT-PCR for POMC mRNA expression (Figure 2 ).
Morphological and histological analysis
Significant beta-endorphin immunoactivity was detected in meningeal cells, pia mater and the lumbar dorsal root entry zone. Some beta-endorphin-positive cells were located in the spinal dorsal horn (Figure 3c ). The most intensive immunoactivity was noted between 3 and 7 days after electroporation, with decreases in the intensity demonstrated for all animals at 21 days. For some samples, immunoactivity was also determined for the Gene Therapy lower thoracic spinal cord at 3 or 7 days, with expression of immunoactivity shown to be plasmid-titer related. For all control groups, no beta-endorphin immunoactivity was noted in the meningeal cells or pia mater at any timepoint ( Figure 3b ). Immunohistochemistry with antiNeuN showed some beta-endorphin immunoactivity located in the neuronal cells of dorsal horn, some located in the nonneuronal cells (Figure 3d ).
Behavior change after intrathecal electroporation
A control group of 12 rats received normal saline, with or without optimal intrathecal electroporation. No specific thermal-withdrawal latency or mechanical-withdrawal latency was noted for these two subgroups (Figures 4a  and 5a ).
Behavioral effects of intrathecal POMC electroporation on established thermal hyperalgesia
Baseline latencies for animals injected intrathecally with POMC plasmid or pEGFP were similar to those for animals treated using intrathecal POMC electroporation. By contrast, significantly increased limb-thermal withdrawal latency (at days 6, 8, 10, 12 and 14 after surgery; Figure  4a ) and mechanical withdrawal latency (at days 4, 6, 8, 10, 12 and 14 days after surgery; Figure 5a ) were demonstrated for intrathecal POMC electroporation in comparison with the controls (P Ͻ 0.05). Notably, a normalized thermal-withdrawal threshold was determined for animals that had undergone intrathecal-POMC on days 12 and 14 post-lesion.
The thermal-hyperalgesia and mechanical withdrawal threshold were also evaluated for a group of contralaterally sham-operated animals. No significant differences Figure 4 Thermal-withdrawal latency was significantly increased for CCI rats at 6, 8, 10, 12 were demonstrated when control and treatment groups were compared (Figures 4b and 5b) .
Naloxone challenge
Intramuscular injection of naloxone 6 days after an intrathecal normal saline injection did not affect either the thermal or mechanical withdrawal latencies in the control animals (group A). However, it reduced the prolonged latencies to the preinjection value 30 min after the injection in animals that received intrathecal POMC plasmid electroporation ( Figure 6 ).
Discussion
In this study, we report the successful implementation of spinal electroporation for delivery of the POMC gene into the lumbar spinal cord. This was achieved using a modified intrathecal-microdialysis catheter that permitted plasmid delivery and application of trans-spinal current, either simultaneously or sequentially. Importantly, no detectable side-effects, such as sensory/motor dysfunction, were noted for any animal using the optimal conditions established by our investigation (200 V, 75 ms, n = 5). For the first part of the study, an adequate transfection efficacy was determined for this optimal combination using Western blotting.
In comparison with previous techniques, this approach has a number of specific advantages: (1) extensive surgical intervention is not required; (2) sufficient induction of effective transfection is achieved in meningeal and pia The cellular distribution of the transferred gene was noted in the meningeal cells, pia mater, and to a less extent, dorsal horn. This method of gene transfer to nonneuronal cells to affect neuronal function is a highly accessible paradigm for gene therapy to spinal cordrelated disease. The nonneuronal meningeal target provides a simple and safe route of administration and allows manipulation of neuronal function. The neuronal target provides direct regulation of pain-related signal transduction in the dorsal horn. The spatial distribution of beta-endorphins provides segmental gene transfer for specific targeting to modulate the excitability of the primary sensory-afferent branching. With improved plasmid design, regulated long-term expression, specific promoter/enhancer elements to targeting gene expression within restricted tissue and/or groups of cells, or further refinement with variations in types of electrodes used (from a fine point to a long wire or plate), this in vivo approach may offer efficacy with just a single treatment. [21] [22] [23] [24] This contrasts with intrathecal drug pumps which require ongoing maintenance and pose a continuous infection risk. Furthermore, multiple genes can also be simultaneously examined by co-electroporation of mixed expression vectors, 25 and blocking gene function or expression is also possible using dominant negative molecules. 26 This novel design is also a powerful approach for the analysis of gene function and regulatory systems.
The proposed approach provides an important additional benefit: the efficacy of beta-endorphin for different types of pain. 27 The reduction in hyperalgesia and allodynia demonstrated in our rat model was not accompanied with changes in response time for the contralateral paw. Other opiate agonists, such as bremazoc-ine and GR89696, also share this selectivity. 28 Further, binding and functional data indicate that beta-endorphin recognizes non-mu, non-delta, non-kappa 1 sites in the spinal cord, termed kappa 2 or epsilon, existing in the spinal cords of a wide variety of genetically distinct human populations. 29, 30 These data suggest that delivery of beta-endorphin's anti-hyperalgesia-specific effects, as induced in the present study, may predict palliative efficiency for neuropathic pain syndromes in humans.
As this is the first report of POMC gene therapy for the treatment of mononeuropathy, and the first use of the intrathecal electroporation probe in such a study, the comparison of gene-transfer efficiency as delivered using other mechanisms such as viral vectors, is impossible. Serious concerns have been raised about the use of viral vectors, however, especially where clinical trials are involved. For this study, the duration of POMC expression, evident between days 14 and 21, was confirmed using Western blot analysis and RT-PCR. This expression interval is comparable with that reported for adenoviral vectors after direct spinal parenchymal transfection. 31 Further, a comparable time-frame has been reported for spinal ␣-motoneuronal ␤-gal expression after peripheral muscle adeno-associated virus (AAV) injection. 32 By comparison with direct spinal AAV injection, for our study, a relatively weak transfection rate was noted for neurons in the deeper regions of the gray matter. Furthermore, the potential for increased parenchymal-transfection efficacy with greater anode proximity to the lumbar spinal cord (ie the contralateral part of the lumbar spinal cord) remains to be determined.
For humans, the spinal cord is an attractive target organ for gene delivery because it can be manipulated percutaneously via a small-gauge spinal needle. Repeat intrathecal treatment through a catheter may be an ideal application of this technology. Pain-killer genes, such as those that produce enkephalin or endorphin, can be expressed in the spinal CSF or dorsal horn to reduce the intensity of chronic pain. In a related application, specific genes regulating tumor-cell suppression or elimination may be delivered directly to affected cells using electroporation. In future, spinal gene transfer may underpin a treatment strategy for hereditary disease and lead to the production of transgenic animals.
In conclusion, this study has demonstrated that it is possible to achieve effective gene expression using spinal electroporation combined with intrathecal plasmid delivery, particularly for meningeal and pia mater cells, and for those localized in the superficial layers. Additionally, the simplicity and reliability of this technique indicates the likelihood of successful implementation for a number of spine-related disorders, for which the increased expression of specific genes is desired. These spinal applications may include traumatic injury, ischemia-induced neuronal degeneration, and tumor and/or pain syndromes.
Materials and methods
Human pro-opiomelanocortin (POMC) cDNA expression plasmid construction
Total RNA from the human pituitary gland was obtained using TriZol Reagent (Gibco, Grand Island, NY, USA). cDNA was synthesized by reverse transcriptase using Gene Therapy oligo-dT as the primer (BcaBEST RNA PCR kit; TaKaRa Biomedicals, Otsu, Japan). The POMC gene was then amplified by PCR using specific upstream and downstream oligonucleotides. The upstream oligonucleotide was 5Ј-CAG ggT aCC TGG AAG ATG CCG AGA TC-3Ј, and the downstream analog was 5Ј-CCT GGG taC CGC TGT GCC CTC ACT CG-3Ј, where lowercase letters indicate changes to incorporate KpnI cutting sites (underlined). The PCR product contained the full-length coding region of the pro-opioidmelanocortin gene, with an expected length of 854 bp. After cloning into a pUC18 vector, white colonies (LacZ mutation) were selected, and plasmid DNA was purified using the Mini Plasmid DNA Preparation Kit (Qiagen, Valencia, CA, USA), digested using KpnI, and electrophoresed on an agarose gel. Plasmids containing the correct insert size were further verified by DNA sequencing. The plasmid insert containing the correctly orientated full-length POMC gene was then cloned into the KpnI site of pCMV-Script (Clontech, Palo Alto, CA, USA). The preparation and purification of the plasmid from cultures of the pCMV-POMC-transformed Escherichia coli was prepared using the column method (Qiagen Mega Kit; Qiagen).
General preparation/electrode construction
After receiving permission from the Institute Review Board of the Chang Gung University, a total of 132 male Sprague-Dawley rats (National Science Council, Taipei, Taiwan), weighing 300-350 g, were studied, with adherence to the guidelines for pain research. 33 An electrodecatheter was implanted intrathecally using a previously described technique. 34 Briefly, a double lumen catheter was constructed using polyethylene (PE-5) tubing and cuprophane hollow fiber dialysis membrane. Before connection of the dialysis membrane (1 cm in length) to one piece of PE-5 tubing (8 cm in length), a nichrome wire (0.0026") was passed into the blind-looped dialysis fiber. The other PE-5 tubing (9 cm in length) served for the intrathecal plasmid injection. The electrode catheter was then implanted into the lumbar (L2-L5) intrathecal space through a cisternal incision. All animals were allowed to recover for 2 days before commencement of the study. Gene transfer was accomplished via direct IT injection of 100 g of pro-opiomelanocortin plasmid or pEGFP (Clontech) according to our previous experiment. 34 The intrathecal electrode was contacted with a negative electrode clamp through the sheath. A positive electrode was placed on the animal's tail, and electric pulses were applied using a pulse generator (BTX; Electrogenetics, Islip, NY, USA).
Immunohistochemistry and morphology studies
Rats were anesthetized with pentobarbital (100 mg/kg, i.p.) and phenytoin (25 mg/kg, i.p.), and transcardially perfused with 100 ml of heparinized saline followed by 250 ml of 4% paraformaldehyde in phosphate buffer (pH = 7.4). Two hours later, the spinal cords were removed and post-fixed in the same fixative for 6 h. After postfixation, tissue was cryoprotected in 30% sucrose overnight, and frozen transverse or parasagittal spinal-cord sections (10 mm) were prepared and stored in phosphate buffer at 4°C. Anti-beta-endorphin (1:160 dilution; Chemicon, Temecula, CA, USA), anti-NeuN (1:100 dilution; Sigma, St Louis, MO, USA) and anti-GFAP (1:100 dilution; Sigma) were used as the primary antibodies, with FITC-conjugated goat anti-rabbit antibody and rhodamine-conjugated goat anti-mouse antibody (1:250 dilution; Jackson ImmunoResearch Laboratories, West Grove, PA, USA) serving as the secondary antibodies. Immunoactivity was detected using a Leica fluorescence microscope. Images (at 512 × 512 pixels) were obtained with a SPOT digital camera and processed using Adobe Photoshop 5.5 software (Adobe Systems, Mountain View, CA, USA).
RT-PCR for POMC mRNA analysis RNA was extracted using a standard TriZol Reagent (Gibco) method with some modifications. Sixty rats were used in these experiments (six rats for every time-point).
Spinal cord segments were homogenized in TRIzol reagent and RNA was precipitated with isopropyl alcohol. Subsequently, the RNA was mixed in a solution consisting of 1 × PCR buffer, 0.01 units/l ribonuclease inhibitor, and 0.04 units/l deoxyribonuclease I. The reaction mixture was incubated at 37°C for 30 min. Immediately after incubation 0.25 g/l proteinase K was added to the reaction mixture and incubated again for 30 min. After precipitation of RNA, complementary DNA synthesis was performed using oligo-d(T) primer, as described by the manufacturer. PCR was performed using an amplification cycle profile consisting of 94°C for 1 min, 62°C for 1 min, and 72°C for 2 min per cycle. After 30 PCR cycles, an additional cycle at 72°C for 7 min was performed to ensure complete DNA extension. Primers for POMC were sense 5Ј-AG ACT GCA AGA TGG TC-3Ј and antisense 5Ј-T GTA CGA CAG CAG GTA-3Ј, yielding a 454-bp product. Primers for the ␤-actin were sense 5Ј-ACA CCC CAG CCA TGT ACG-3Ј and antisense 5Ј-TGG TGG TGA AGC TGT AGC C-3Ј, yielding a 225-bp product. Each RT-PCR product ran through an agarose gel (3%) and was visualized with ethidium bromide. The relative abundance of the RT-PCR product was determined by an imaging densitometer (model GS-710; BioRad, Hercules, CA, USA), and results were expressed as a ratio of POMC divided by ␤-actin.
Western blot
Total protein concentrations were then determined using a BCA protein assay (Pierce, Rockford, IL, USA). Fifteen micrograms of total protein was run on a 10% SDS-PAGE gel and transferred to a PVDF membrane. The primary antibody (1:875 dilution of rabbit polyclonal anti-endorphin; Chemicon) was added for 30 min at 37°C in fresh blocking buffer. The membranes were washed for 30 min in washing buffer at room temperature, before the secondary antibody (1:16 000 dilution of horseradish peroxidase-coupled goat anti-rabbit IgG; Sigma) was added for 1 h at room temperature in blocking buffer. The membranes were washed in washing buffer for another 30 min, and the antibodies were then revealed using Western Blot Chemiluminescence Reagent Plus (NEN, Boston, MA, USA). For densitometric analysis, blots were scanned using the Model GS-710 imaging densitometer, and results expressed as the ratio of beta-endorphin immunoreactivity to ␤-actin immunoreactivity.
Experimental design
For the first set of experiments, animals received POMC plasmid DNA using a range of different conditions (voltage: 50, 100, 150, 200, 250 V, duration of electroporation pulse: 25, 50, 75, 100 ms, number of shocks: 1, 3, 5, 7, 9), with the beta-endorphin levels determined using Western blot 7 days after electrotransfection. The timecourse for POMC gene expression was also determined. For the second set of experiments, animals (n = 10/group) were randomly assigned to one of five treatment groups. Depending upon group designation, the animals received: saline only, saline with electroporation, pEGFP with electroporation, POMC plasmid only, or POMC plasmid with electroporation, administered immediately post-sciatic nerve injury. The thermal nociceptive threshold was measured before CCI, and then on even-numbered days, up to and including the 14th day, to assess and compare the therapeutic effects of the intrathecal electroporation.
Behavioral assessment of thermal and mechanical stimulation
The thermal nociceptive threshold was measured before and after induction of the nerve injury, or after intrathecal electroporation, using a technique somewhat modified from that originally described by Hargreaves et al. 35 The animal was placed on a glass plate (maintained at 30°C) for 5-10 min for adaptation. Latency between application of a focused light beam and hind-paw withdrawal response was measured to the nearest 0.1 s, with a cut-off time in the absence of response of 20 s.
Foot withdrawal threshold in response to a mechanical stimulus was determined using a series of von Frey filaments (Stoelting, Wood Dale, IL, USA), ranging from 0.23 to 59.0 g. Animals were placed in a plastic cage with a metal mesh floor, allowing them to move freely. They were allowed to acclimatize to this environment before the experiment. The filaments were presented to the midplantar surface as described previously.
Naloxone challenge
To determine whether the analgesic effect after the transplantation was induced by b-EP, we intramuscularly injected six rats in each group with 1 mg/kg naloxone (Nacalai Tesque, Kyoto, Japan) 7 days after the operation. Pain sensitivity was measured by thermal and mechanical withdrawal latency measured by hot plate latency at every 30 min until 90 min after the injection.
Data analysis
All data were expressed as the mean ± s.e.m. Statistical evaluation of the thermal latency in the thermal test and the hind-paw withdrawal threshold in the von Frey hair test was performed in each group with one-way repeated measures analysis of variance. Statistical comparisons between groups for the thermal test, the von Frey hair test, and beta-endorphin gene expression were performed by one-way factorial analysis of variance followed by a multiple comparison test (the Bonferroni test). A Pvalue of Ͻ0.05 was considered statistically significant.
